Allergic asthma therapeutics are drugs used to treat patients suffering from allergic asthma. Asthma is caused by inflammation and constriction of the airways when exposed to certain triggers like allergens, dust, pollen, smoke etc. The therapeutics include corticosteroids, bronchodilators, monoclonal antibodies, immunomodulators etc which provide relief from symptoms and prevent exacerbations.
Market key trends:
One of the key trends fueling the growth of allergic asthma therapeutics market is rising adoption of biologics. Biologics like monoclonal antibodies have revolutionized treatment for allergic asthma with their targeted mechanism of action against key mediators of inflammation like interleukin-5 and immunoglobulin E. Drugs like Benralizumab, Mepolizumab, Omalizumab have demonstrated high efficacy in reducing exacerbations and improving quality of life in patients. Their specialty and high cost makes them beneficial for severe allergic asthma patients who remain uncontrolled despite conventional therapies. This has led to biologics emerging as a preferred line of treatment replacing traditional drugs and driving significant revenues in the market.
The allergic asthma therapeutics market is segmented by drug class into anti-inflammatory drugs, bronchodilators, monoclonal antibodies, and others. The anti-inflammatory drugs segment dominated the market in 2022, accounting for over 30% share. Anti-inflammatory drugs such as corticosteroids and leukotriene modifiers are commonly used in the treatment of allergic asthma as they help reduce inflammation in the airways.
The Global Allergic Asthma Therapeutics Market Demand is expected to witness high growth, exhibiting a CAGR of 3.0% over the forecast period, due to increasing air pollution levels.
North America dominated the global market accounting for over 35% share in 2022 owing to growing prevalence of asthma in the US and Canada. Asia Pacific is anticipated to witness fastest growth during the forecast period supported by expanding healthcare infrastructure and growing medical tourism industry in the region.
Key players operating in the allergic asthma therapeutics market are ASLAN Pharmaceuticals, Takeda Pharmaceutical Company Limited, CHIESI Farmaceutici S.p.A., CSL, NIOX, Fountain Therapeutics, Eli Lilly and Company, GSK plc., Infinity Pharmaceuticals, Inc., Mabtech, Kineta Inc., Marinomed Biotech AG, Mycenax Biotech Inc., AstraZeneca, and Panacea Biotec. These players are focusing on developing novel biologics for effectively treating allergic asthma.